Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Structure of Cannabinoid Receptor Elucidated In New Study

XTALKS VITALS NEWS

Cannabis

According to the researchers, having a better understanding of how THC and synthetic cannabinoids interact with the receptor could help uncover some of the benefits and risks of cannabis use.

Share this!

October 24, 2016 | by Sarah Hand, M.Sc.

While researchers have long known that one of the active component in cannabis – known as tetrahydrocannabinol (THC) – acts on the cannabinoid receptors in the brain, the mechanisms behind this interaction were previously unknown. Now, researchers have uncovered the structure of the cannabinoid receptor 1 (CB1), in a study which was published in the journal Cell.

Using this crystal structure, the researchers were able to create a 3-D model of the CB1 receptor. According to the researchers, having a better understanding of how THC and synthetic cannabinoids interact with the receptor could help uncover some of the benefits and risks of cannabis use.

“With marijuana becoming more popular with legislation in the United States, we need to understand how molecules like THC and the synthetic cannabinoids interact with the receptor,” said co-author Raymond Stevens, a professor of Biological Science and Chemistry at the University of Southern California, “especially since we're starting to see people show up in emergency rooms when they use synthetic cannabinoids.”



According to the researchers, it’s unknown why THC derived from Cannabis sativa has such a high safety margin, compared to synthetic cannabinoids which can cause serious side effects in certain doses. Their research on the structure of CB1 could help drugmakers design safer therapeutics capable of acting on the receptor.

By synthesizing a synthetic cannabinoid known as AM6538, Stevens and his team were able to determine the conformation of the CB1 receptor. When studying the 3-D model of the CB1 receptor, the researchers identified multiple regions which may explain how THC and synthetic cannabinoids produce psychoactive effects on the body.

“Researchers are fascinated by how you can make changes in THC or synthetic cannabinoids and have such different effects,” said Stevens. “Now that we finally have the structure of CB1, we can start to understand how these changes to the drug structure can affect the receptor.”


Keywords: Cannabis, Drug Development, Drug Receptor


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Researchers Identify Role of ApoE4 Gene as Possible Drug Target in Alzheimer’s Disease

September 21, 2017 - A team of neurology researchers at Washington University School of Medicine in St. Louis have found that in the presence of the ApoE4 protein, another protein known as tau forms tangles in the brain which contributes to neuronal damage characteristic of Alzheimer’s disease.

Featured In: Life Science News


New Guidelines Address CAR-T Immunotherapy Toxicities to Prevent Patient Deaths

September 20, 2017 - Clinicians at The University of Texas MD Anderson Cancer Center have published new guidelines in the journal, Nature Reviews Clinical Oncology, which could help in the management of these toxicities.

Featured In: Biotech News, Drug Safety News


Microneedle Skin Patch Could Treat Common Metabolic Disorders

September 19, 2017 - Researchers at Columbia University Medical Center (CUMC) and the University of North Carolina have developed a microneedle skin patch impregnated with a drug capable of converting white fat into calorie-burning brown fat.

Featured In: Medical Device News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Five Reasons Why Toronto is Emerging as a Major Life Sciences Hub

REGISTER FOR THESE WEBINARS

Development and Manufacture of Highly Potent API Drug Products Throughout the Clinical Phases


Innovation through Integration – Providing Next Generation Biomedical Devices and Interconnects


Clinical Payments Case Studies: Improving Efficiency, Cash Management, and Compliance


Why Phase 3 Trials Fail: Oncology Case Studies and Lessons Learned


Copyright © 2016-2017 Honeycomb Worldwide Inc.